JENKEM(SH:688356) EBSCN·2025-09-03 08:57Investment Rating - The report maintains a "Buy" rating for the company, considering the significant growth in overseas revenue and the promising application space for its drug and medical device projects [4]. Core Insights - The company is undergoing a performance transformation period, with orderly progress in new drug and medical beauty projects. In H1 2025, the company achieved operating revenue of 130 million yuan, a year-on-year increase of 0.89%, while the net profit attributable to the parent company was 22 million yuan, a decrease of 21.08% [1][4]. - Domestic sales have decreased while exports have increased. The main business revenue remained stable compared to the same period last year, with product sales revenue at 125.56 million yuan, down 0.26% year-on-year, and technical service revenue at 3.78 million yuan, up 83.77% year-on-year. Domestic sales revenue was 20.48 million yuan, down 58.35%, while export revenue was 105.08 million yuan, up 36.96% [2][3]. Summary by Sections Financial Performance - In H1 2025, the company reported a total R&D investment of 42.60 million yuan, an increase of 52.44% year-on-year, with R&D investment accounting for 32.84% of operating revenue, up 11.11 percentage points year-on-year. The company is advancing its clinical trials for new drugs and has received regulatory approvals for its medical beauty devices [3][4]. Profit Forecast and Valuation - The profit forecast for the company remains at 53 million yuan for 2025, 124 million yuan for 2026, and 172 million yuan for 2027. The report highlights the potential for significant growth in overseas revenue and the development of its drug and device pipeline [4][10].